

Natco Pharma to launch Baricitinib tablets for COVID-19 treatment

04 May 2021 | News

Baricitinib in combination with Remdesivir is used for treatment of COVID-19 positive patients

Natco Pharma has received Emergency Use (EU) approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India.

Baricitinib in combination with Remdesivir is used for treatment of COVID-19 positive patients.

Hyderabad based Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the pandemic. The company is ready to launch the product this week, so as to make the product available to suffering patients across India.

Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis.